# US 2005/0232912 A1 · Enzyme phosphorylating ser46 of p53

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0232912 A1
- Document ID: US20050232912A1
- Status: Published application
- Kind: A1
- Application number: 10/490,454
- Filed: 2002-09-25
- Published: 2005-10-20
- Earliest claimed: 2001-09-26
- Inventors: Yoichi Taya; Tomoaki Tanaka; Yusuke Nakamura; Hirofumi Arakawa
- Web page: https://patentgrep.com/patent/US20050232912A1

## CPC

- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- A61P 35/00: Antineoplastic agents
- C07K 14/4747: {Apoptosis related proteins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The inventors clarified the enzyme phosphorylating the serine residue at amino acid position 46 of tumor suppressor protein p53 and further elucidated the mechanism in regulation of inducibility of apoptosis by p53. As the results, the inventors provide a completely new enzyme comprising casein kinase 2 and p53DINP1

## Claims

### Claim 1

An enzyme comprising casein kinase 2 and p53DINP1.

### Claim 2

An enzyme comprising at least one selected from the group consisting of proteins having one of the amino acid sequences of sequence numbers 1 to 3 and also at least one selected from the group consisting of proteins having one of the amino acid sequences of sequence numbers 4 and 5.

### Claim 3 (depends on 2)

The enzyme of claim 2, wherein one or a few amino acid(s) is/are deleted, substituted or added in said amino acid sequences of sequence numbers 1 to 5.

### Claim 4

An enzyme, which is a nuclear fraction obtained during purification of cells with activated p53, said nuclear fraction reacting with an antibody specific to an antigen that comprises a peptide fragment of p53 containing Ser46, said Ser46 being phosphorylated, when p53 being added to said nuclear fraction, and reacts with an antibody specific to casein kinase 2.

### Claim 5 (depends on 4)

The enzyme of claim 4, which further reacts with an antibody specific to p53DINP1.

### Claim 6 (depends on 1)

An anti-tumor agent comprising the enzyme of claim 1 as an effective component.

### Claim 7 (depends on 1)

A screening agent for drugs activating specifically p53, comprising the enzyme of claim 1 as an effective component.

### Claim 8 (depends on 1)

A screening agent for drugs inhibiting the enzyme of claim 1, comprising said enzyme as an effective component.

### Claim 9 (depends on 1)

A method of using the enzyme of claim 1 as an anti-tumor agent.

### Claim 10 (depends on 1)

A method of using the enzyme of claim 1 as a screening agent for drugs activating specifically p53.

### Claim 11 (depends on 1)

A method of using the enzyme as of claim 1 as a screening agent for drugs inhibiting the activity of said enzyme.
